atezolizumab + RO7122290

Atezolizumab + RO7122290 is a combination investigational immunotherapy comprised of atezolizumab, an anti–PD-L1 monoclonal antibody, and RO7122290, a tumor-targeted 4-1BB (CD137) agonist fusion protein that binds fibroblast activation protein-α (FAP) on cancer-associated fibroblasts and costimulates T cells and natural killer cells. This combination aims to simultaneously inhibit the PD-L1 pathway and stimulate CD137, with RO7122290 specifically designed to localize its effect to FAP-rich tumor microenvironments, thereby enhancing antitumor immune responses and minimizing systemic toxicity. Clinical data show increased peripheral and intratumoral proliferating CD8+ T cells and activation gene signatures, with promising activity in patients with advanced solid tumors[1][4][7][9].

Brand names

Tecentriq

Other names

RG7827RG-7827RG 7827FAP-4-1BBLFAP4-1BBLFAP 4-1BBL